middle.news
CSL Backs Potential Rare Disease Franchise With Lixudebart Deal
8:22am on Monday 5th of October, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
CSL Backs Potential Rare Disease Franchise With Lixudebart Deal
8:22am on Monday 5th of October, 2026 AEDT
Key Points
US$355 million upfront payment to Alentis Therapeutics
Up to US$1.2 billion in commercial milestones
CSL to fund Phase 2 and planned Phase 3 development
Global profits to be split 55% CSL and 45% Alentis
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE